Get the app
US › Healthcare

Bright Minds Biosciences Inc (DRUG)

US · Healthcare · Biotechnology

$23.00+11.11%
Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-2.5M
EPS
$-0.17
EPS estimate
$-1.39

EPS came in at -0.17 against a street estimate of -1.39 — a beat of 87.8%.

Key statistics

Market cap
$542.3M
Forward P/E
0.0
P/B
2.47
Book value
$22.22
EPS (TTM)
$-2.05
52-week high
$123.75
52-week low
$18.90
50-day MA
$59.18
200-day MA
$73.27
Beta
0.23

Analyst view

Analysts rate Bright Minds Biosciences Inc a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $154.86.

Shareholding

Insiders
11.49%
Institutions
94.90%

Largest institutional holders

FundStake
Jupiter Topco LLC13.68%
Cormorant Asset Management, LLC9.12%
BlackRock Inc6.96%
Vivo Capital, LLC5.65%
Vestal Point Capital LP5.53%
BRAIDWELL LP4.90%
Driehaus Capital Management LLC4.39%
Balyasny Asset Management LLC3.50%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bright Minds Biosciences Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-11-07.